Fig 2: ARHGEF6 has the potential to predict immunotherapy. (A–C) Single-cell analysis of ARHGEF6. (D) Correlation between ARHGEF6 expression and 6 types of immune cells in the TISIDB database. (E) Correlation between ARHGEF6 expression and 7 types of immune checkpoints in the TISIDB database.

Fig 3: The results of immunohistochemical staining in LUAD. (A) ARHGEF6 expression in LUAD tissue (a,b) and normal lung tissue (c,d). (B) ARHGEF6 expression in high TMB tissue (e,f) and low TMB issue (g,h). (a,c,e,g) Magnification, ×2.5; (b,d,f,h) Magnification, ×10.

Fig 4: Drug Sensitivity Analysis of ARHGEF6. (A–H) Correlation of ARHGEF with eight drugs, including camptothecin, cisplatin, crizotinib, dabrafenib, docetaxel, erlotinib, gemcitabine, and paclitaxel. (*P < 0.05, **P < 0.01, ***P < 0.001, G1:low-expression; G2:high-expression).

Fig 5: ARHGEF6 may serve as a new prognostic marker for lung adenocarcinoma (LUAD). (A) ARHGEF6 mRNA levels in different tumor types were determined by TIMER2.0. (B) ARHGEF6 expression in TCGA database paired lung adenocarcinoma data. (C) ARHGEF6 expression was significantly negatively correlated with OS in TCGA. (D–G) Relationship between ARHGEF6 and clinicopathological parameters. (H–I) Univariate and multifactorial analysis of ARHGEF6. (*P < 0.05, **P < 0.01, ***P < 0.001).